Jump to content
RemedySpot.com

Janssen Seeks European Marketing Authorization For Investigational Hepatitis C Treatment Telaprevir

Rate this topic


Recommended Posts

Posted

Janssen Seeks European Marketing Authorization For

Investigational Hepatitis C Treatment Telaprevir

20 Dec 2010

Janssen-Cilag International NV announced the submission of a

Marketing Authorisation Application (MAA) to the European Medicines

Agency (EMA) for telaprevir, an investigational, oral, direct-acting

antiviral for the treatment of chronic genotype 1 hepatitis C virus

(HCV), the most common form of the virus. Telaprevir is a potent and

selective protease inhibitor (PI), which when combined with

pegylated-interferon and ribavirin (the current treatment standard),

shows activity in patients that are new to treatment and who have

been previously treated but were not cured, including partial

responders, relapsers and those who have had little or no response

(null responders) to the current standard of treatment.

The EMA has accepted telaprevir for accelerated assessment, which is

granted to quicken access to innovative, new medicines of major

public-health interest. Tibotec BVBA, a global research and

development company with specific experience in virology, is

developing telaprevir in collaboration with Vertex Pharmaceuticals.

Tibotec BVBA is an affiliate company of Janssen.

"The EMA submission for telaprevir is a landmark in the treatment of

HCV and demonstrates our dedication to addressing unmet medical

needs by developing innovative treatments for infectious diseases,"

said Johan Van Hoof, Global Therapeutic Area Head Infectious

Diseases and Vaccines at Janssen. "Above all, it is an important

step towards making telaprevir available to people living with HCV."

It is estimated that 170 million people are living with HCV around

the world, including more than five million in Europe. Chronic HCV

can result in serious long-term health problems, and an estimated 30

percent of patients will develop progressive liver disease,

including cirrhosis (damage and scarring of the liver), which places

them at risk for liver insufficiency and liver cancer. HCV is the

most common cause of liver transplant in Europe.

The current standard of care for HCV genotype 1 patients,

pegylated-interferon and ribavirin, is administered for 48 weeks and

only 40 to 50 percent of genotype 1 patients achieve a sustained

virologic response (SVR), defined as achieving undetectable levels

of the virus in the blood for six months after completion of

treatment, and considered an indicator of cure. Re-treatment with

pegylated-interferon and ribavirin in patients who have previously

failed this treatment shows only limited success. ,

The EMA submission is supported by results from three phase 3

studies, which compared telaprevir in combination with the current

standard of treatment to the current standard of treatment alone in

HCV genotype 1 patients. Results were very positive:

- Significantly higher SVR rates were observed in treatment-naïve

patients treated with telaprevir compared to the current standard

treatment of pegylated-interferon and ribavirin (75 percent vs. 44

percent)

- The majority of patients were cured by week 24, which is half the

duration of therapy with the current standard of treatment8,

- There was a three-fold increase in cure rates (65 percent vs. 17

percent) across all types of previously treated patients who were

given telaprevir compared to the current treatment standard,

including prior null responders (31 percent vs. 5 percent) 10

- The most common adverse events in the telaprevir-based treatment

groups were fatigue, pruritus, nausea, headache, anemia, rash,

influenza-like illness, insomnia, fever and diarrhea. The majority

of these adverse events were mild to moderate.8,9,10

"Current treatment for hepatitis is lengthy and only effective for

approximately half of treatment-naïve patients, and even fewer

patients who failed previous treatment," commented Stefan Zeuzem,

Professor of Medicine and Chief, department of medicine, J W Goethe

University Hospital, furt. "If approved, telaprevir would help

to significantly improve cure rates and shorten treatment duration

for many people living with HCV, compared to current standard

treatment."

About the Telaprevir Development Program

To date, more than 2,500 people with HCV genotype 1 have received

telaprevir-based therapy (telaprevir combined with the current

standard of treatment) as part of Phase 2 studies and the Phase 3

ADVANCE, ILLUMINATE and REALIZE trials.8,9,10 The telaprevir

clinical development program is the largest conducted to date for

any investigational direct-acting antiviral hepatitis C therapy.

- ADVANCE evaluated telaprevir-based regimens in approximately 1,088

treatment-naïve patients with chronic HCV infection. Data from the

ADVANCE trial were presented at the 2010 American Association for

the Study of Liver Diseases (AASLD) annual meeting in November

2010.8

- ILLUMINATE evaluated the benefits of extending telaprevir-based

therapy in 540 treatment-naïve patients whose HCV was undetectable

at weeks 4 and 12 of treatment. 322 of these patients were

randomized to receive 24 or 48 weeks of treatment, and it was found

that there was no benefit to extending treatment to 48 weeks. Data

from the ILLUMINATE meeting were presented at AASLD in November

2010.9

- REALIZE evaluated telaprevir-based regimens in approximately 650

treatment-failure HCV patients. Data from the REALIZE trial will

likely be published in 2011.

Telaprevir is being developed by Tibotec BVBA, an affiliate company

of Janssen, in collaboration with Vertex Pharmaceuticals and

Mitsubishi Tanabe Pharma for the treatment of genotype 1 HCV in

combination with pegylated-interferon and ribavirin in both patients

who have failed prior treatment and those who have never been

treated. Tibotec BVBA has the commercialisation rights for

telaprevir in Europe, Latin America, the Middle East, Africa, India,

Australia and New Zealand, pending approval by the respective

regulatory authorities. Vertex will commercialise telaprevir in the

U.S., Canada and Mexico and Mitsubishi Tanabe Pharma has rights to

commercialise telaprevir in Japan and certain Far East countries.

About Tibotec BVBA

Tibotec BVBA is a global pharmaceutical and research development

company. The Company's main research and development facilities are

in Beerse, Belgium with offices in Titusville, NJ and Cork, Ireland.

Tibotec is dedicated to the discovery and development of innovative

HIV/AIDS and HCV drugs, and anti-infectives for diseases of high

unmet medical need.

References

1. The Hepatitis C Trust. The hepatitis C virus: Genotypes of HCV.

[cited 2010 Nov 11] Available here.

2. World Health Organization. Hepatitis C, surveillance and control.

[cited 2010 November 29] Available here.

3. Biggins SW. Treatment of recurrent hepatitis C after liver

transplantation. Infect Dis Clin North Am. 2006 Mar;20(1):155-74.

4. Buskila D. Hepatitis C Associated Rheumatic Disorders. Rheum Dis

Clin N Am. 2009;35:111-123.

5. Lang K, Weiner DB. Expert Rev Vaccines. "Immunotherapy for HCV

infection: next steps." 2008;7(7): 915-923.

6. The Hepatitis C Trust. Introduction: Potential New Drugs. [cited

2010 Oct 19] Available here.

7. The Hepatitis C Trust. Treatment: Retreatment. [cited 2010 Oct

19] Available here.

8. McHutchison, J, son, I, and Dusheiko, G et al.

Telaprevir in Combination with Peginterferon and Ribavirin in

Genotype 1 HCVTreatment-Naive Patients: Final Results of Phase 3

ADVANCE Study. Presented at AASLD 2010. Boston, USA.

9. Sherman, K, Flamm, S, and Afdhal, N et al. Telaprevir in

Combination with Peginterferon and Ribavirin in Genotype 1

HCVTreatment-Naive genotype 1 HCV Patients who achieved an Extended

Rapid Viral Response: Final Results of Phase 3 ILLUMINATE Study.

Presented at AASLD 2010, Boston, USA

10. Janssen data on file

Source:

Janssen-Cilag International NV

Article URL: http://www.medicalnewstoday.com/articles/211963.php

--

Bill Eastman

www.ke5asu.com/links.html

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...